TABLE 1

Cancer Incidence Rates and APC of Rates in Children and Adolescents (Ages 0–19 Years) by Gender, United States, 2001–2009

ICCC GroupBoys and GirlsBoysGirls
CountRateaAPCb (95% CI)CountRateaAPCb (95% CI)CountRateaAPCb (95% CI)
All ICCC groups combined120 137171.010.3 (−0.1 to 0.7)64 651179.630.2 (–0.4 to 0.8)55 486161.960.4 (–0.1 to 0.9)
I Leukemias, myeloproliferative, myelodysplastic diseases31 82445.360.5 (−0.3 to 1.3)17 87149.740.4 (–0.5 to 1.3)13 95340.750.6 (–0.6 to 1.9)
 I(a) Lymphoid leukemias22 83432.590.7 (−0.2 to 1.5)13 05236.370.7 (–0.2 to 1.5)978228.600.7 (–0.6 to 1.9)
 I(b) Acute myeloid leukemias55427.880.2 (−1.4 to 0.9)29398.16−1.2 (–3.5 to 1.1)26037.580.9 (–0.3 to 2.1)
 I(c) Chronic myeloproliferative diseases15492.201.7 (−0.9 to 4.3)8132.252.8 (–0.5 to 6.2)7362.140.4 (–3.3 to 4.2)
 I(d) Myelodysplastic syndrome, other myeloproliferative10491.490.2 (−3.0 to 2.6)5841.61−0.4 (–4.4 to 3.9)4651.350.0 (–4.3 to 4.5)
 I(e) Unspecified and other specified leukemias8501.210.1 (−3.8 to 4.1)4831.340.6 (–4.2 to 5.6)3671.07−0.7 (–5.1 to 4.0)
II Lymphomas and reticuloendothelial neoplasms17 44524.910.5 (−0.2 to 1.3)10 38728.970.8 (–0.3 to 1.9)705820.640.1 (–0.9 to 1.2)
 II(a) Hodgkin’s lymphomas878012.500.5 (−0.3 to 1.3)467813.010.5 (–0.7 to 1.7)410211.980.5 (–1.1 to 2.0)
 II(b) Non-Hodgkin’s lymphomas (except Burkitt lymphoma)60478.660.7 (−0.5 to 1.8)382110.671.3 (0.0 to 2.5)22266.53−0.4 (–1.3 to 0.6)
 II(c) Burkitt lymphoma17122.47−0.1 (−2.7 to 2.7)13593.830.0 (–2.9 to 2.9)3531.040.1 (–4.7 to 5.1)
 II(d) Miscellaneous lymphoreticular neoplasms6630.931.2 (−4.0 to 6.6)3921.082.4 (–4.0 to 9.2)2710.78−0.3 (–6.3 to 6.1)
 II(e) Unspecified lymphomas2430.350.4 (−5.7 to 6.8)1370.381060.31
III CNS and miscellaneous intracranial and intraspinal neoplasms21 13530.28−0.1 (−1.0 to 0.8)11 37731.84−0.3 (–1.4 to 0.9)975828.650.1 (–1.1 to 1.4)
 III(a) Ependymomas and choroid plexus tumor18002.56−1.5 (−4.5 to 1.7)9862.740.0 (–3.4 to 3.5)8142.37−3.2 (–7.1 to 0.8)
 III(b) Astrocytomas10 53315.10−0.1 (−1.2 to 0.9)552915.48−0.4 (–1.6 to 0.9)500414.710.1 (–1.6 to 1.8)
 III(c) Intracranial and intraspinal embryonal tumors43646.24−0.6 (−1.9 to 0.8)25917.25−1.1 (−2.0 to −0.1)c17735.180.2 (–2.1 to 2.5)
 III(d) Other gliomas36535.260.9 (−0.6 to 2.4)18565.220.3 (–1.4 to 1.9)17975.301.6 (–0.6 to 3.8)
 III(e) Other specified intracranial/intraspinal neoplasms4620.66−1.2 (−4.9 to 2.7)2460.69−1.0 (–5.4 to 3.6)2160.63−1.4 (–6.5 to 4.0)
 III(f) Unspecified intracranial and intraspinal neoplasms3230.464.4 (0.1 to 8.9)c1690.471540.45
IV Neuroblastoma, other peripheral nervous cell tumors58708.21−1.2 (−3.0 to 0.8)31218.53−0.5 (–2.9 to 2.0)27497.87−2.0 (–4.0 to 0.1)
 IV(a) Neuroblastoma and ganglioneuroblastoma57268.00−1.2 (−3.1 to 0.6)30438.31−0.5 (–3.0 to 1.9)26837.68−2.1 (–4.1 to 0.0)c
 IV(b) Other peripheral nervous cell tumors1440.20780.22660.19
V Retinoblastoma21693.01−0.2 (−1.8 to 1.5)11002.99−1.6 (−3.6 to 0.3)10693.031.4 (–1.1 to 3.9)
VI Renal tumors46976.640.5 (−0.3 to 1.3)22286.150.0 (−1.5 to 1.5)24697.151.1 (–1.3 to 3.2)
 VI(a) Nephroblastoma, other nonepithelial renal tumors42486.000.0 (−0.7 to 0.8)20065.53−0.4 (−1.9 to 1.1)22426.490.4 (–1.7 to 2.5)
 VI(b) Renal carcinomas4260.615.4 (2.8 to 8.1)c2100.594.2 (1.4 to 7.0)c2160.63
 VI(c) Unspecified malignant renal tumors230.03
VII Hepatic tumors14772.071.7 (−1.7 to 5.3)8742.402.8 (–1.4 to 7.2)6031.730.1 (–4.1 to 4.4)
 VII(a) Hepatoblastoma10501.461.6 (−2.2 to 5.6)6341.732.4 (–1.9 to 6.8)4161.180.3 (–4.8 to 5.7)
 VII(b) Hepatic carcinomas4110.592.1 (−0.7 to 4.9)2290.643.8 (–0.7 to 8.5)1820.530.2 (–3.8 to 4.4)
 VII(c) Unspecified malignant hepatic tumors160.02
VIII Malignant bone tumors62859.02−0.6 (−1.3 to 0.2)358210.00−0.5 (–2.1 to 1.1)27037.98−0.7 (–1.8 to 0.5)
 VIII(a) Osteosarcomas35465.09−0.4 (−1.7 to 1.0)20165.63−0.9 (–2.7 to 0.9)15304.520.3 (–2.3 to 3.1)
 VIII(b) Chondrosarcomas2480.35−3.1 (−11.1 to 5.6)1580.44900.26
 VIII(c) Ewing tumor and related sarcomas of bone20542.95−1.0 (−3.2 to 1.4)11853.31−0.3 (–4.0 to 3.7)8692.56−1.9 (–3.8 to 0.0)c
 VIII(d) Other specified malignant bone tumors3000.43−1.3 (−6.8 to 4.5)1460.411540.45
 VIII(e) Unspecified malignant bone tumors1370.20770.21600.18
IX Soft tissue and other extraosseous sarcomas841912.010.3 (−0.4 to 1.0)462012.860.0 (–1.0 to 1.1)379911.120.6 (–1.1 to 2.4)
 IX(a) Rhabdomyosarcomas32994.71−0.7 (−3.0 to 1.7)19425.42−1.1 (–3.0 to 1.0)13573.97−0.1 (–4.2 to 4.2)
 IX(b) Fibrosarcomas, peripheral nerve, other fibrous9401.33−0.7 (−3.8 to 2.6)4951.37−2.3 (–5.6 to 1.0)4451.301.2 (–3.5 to 6.2)
 IX(c) Kaposi sarcoma260.04200.06
 IX(d) Other specified soft tissue sarcomas33044.710.9 (−1.0 to 2.9)17254.801.5 (–1.4 to 4.5)15794.630.3 (–2.3 to 3.0)
 IX(e) Unspecified soft tissue sarcomas8501.212.8 (−0.4 to 6.2)4381.221.0 (–4.4 to 6.7)4121.215.1 (–0.6 to 11.0)
X Germ cell, trophoblastic tumors, neoplasms of gonads781411.050.7 (−0.5 to 2.0)496813.651.1 (–0.7 to 2.6)28468.300.5 (–1.3 to 2.2)
 X(a) Intracranial and intraspinal germ cell tumors11331.620.8 (−1.6 to 3.2)8312.32−1.7 (–1.3 to 4.8)3020.89−1.3 (–7.3 to 5.0)
 X(b) Extracranial and extragonadal germ cell tumors10461.46−2.0 (−3.9 to −0.2)c4571.251.7 (–3.8 to 0.4)5891.68−2.3 (−4.5 to −0.1)c
 X(c) Malignant gonadal germ cell tumors51427.271.1 (−0.6 to 2.9)36189.911.0 (–1.1 to 3.2)15244.481.5 (–0.5 to 3.5)
 X(d) Gonadal carcinomas2810.405.3 (−0.5 to 11.4)240.072570.755.9 (–0.3 to 12.4)
 X(e) Other and unspecified malignant gonadal tumors2120.30380.111740.51
XI Other malignant epithelial neoplasms and melanomas12 42817.640.8 (0.1 to 1.5)c427711.85−0.1 (–1.6 to 1.4)815123.771.3 (0.4 to 2.2)c
 XI(a) Adrenocortical carcinomas1510.21550.15960.28
 XI(b) Thyroid carcinomas48126.834.9 (3.2 to 6.6)c9342.594.7 (0.9 to 8.7)c387811.314.9 (3.2 to 6.5)c
 XI(c) Nasopharyngeal carcinomas4120.590.0 (−4.8 to 5.1)2750.762.7 (–3.0 to 8.7)1370.40
 XI(d) Malignant melanomas40475.74−3.8 (−6.7 to −0.9)c16994.70−5.3 (−8.4 to −2.1)c23486.84−2.8 (–6.4 to 1.1)
 XI(e) Skin carcinomas580.08280.08300.09
 XI(f) Other and unspecified carcinomas29484.191.1 (−0.1 to 2.3)12863.562.4 (0.2 to 4.6)c16624.860.1 (–2.2 to 2.4)
XII Other and unspecified malignant neoplasms5740.810.6 (−2.9 to 4.3)2460.683.8 (0.4 to 7.3)c3280.95−1.6 (–6.7 to 3.9)
  • a Rates are per million and were age-adjusted to the 2000 US standard population (19 age groups, Census P25-1130) standard. Rate statistics were not displayed if case count was <16 cases.

  • b APCs were calculated by using weighted least squares method. Statistical significance was determined if the 95% CI of APC did not include zero (P < .05). APC was not calculated if case count was <16 cases in any 1 year. Some significant values appear to include zero because APC was rounded to the nearest 10th.

  • c Denotes significant APC.